Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101 - Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI

BMC Cancer

Ian Paterson¹  Joseph J Pagano³  Kelvin Chow³  Gavin Oudit¹  Sheri Koshman¹  Justin Ezekowitz¹  Richard B Thompson³  John R Mackey²  Mark Haykowsky³  Edith Pituskin² 

[1]Department of Cardiology, Walter McKenzie Center, Edmonton, Alberta, Canada

[2]Cross Cancer Institute, Edmonton, Alberta, Canada

[3]University of Alberta, Edmonton, Alberta, Canada

关键词: Breast cancer;    Trastuzumab;    Cardiac remodeling;    Heart failure;    Cardiotoxicity;   

Others  :  1080817
DOI  :  10.1186/1471-2407-11-318

 received in 2011-06-27, accepted in 2011-07-27,  发布年份 2011

【 摘 要 】

Background

MANTICORE 101 - Breast (Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research) is a randomized trial to determine if conventional heart failure pharmacotherapy (angiotensin converting enzyme inhibitor or beta-blocker) can prevent trastuzumab-mediated left ventricular remodeling, measured with cardiac MRI, among patients with HER2+ early breast cancer.

Methods/Design

One hundred and fifty-nine patients with histologically confirmed HER2+ breast cancer will be enrolled in a parallel 3-arm, randomized, placebo controlled, double-blind design. After baseline assessments, participants will be randomized in a 1:1:1 ratio to an angiotensin-converting enzyme inhibitor (perindopril), beta-blocker (bisoprolol), or placebo. Participants will receive drug or placebo for 1 year beginning 7 days before trastuzumab therapy. Dosages for all groups will be systematically up-titrated, as tolerated, at 1 week intervals for a total of 3 weeks. The primary objective of this randomized clinical trial is to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer, as measured by 12 month change in left ventricular end-diastolic volume using cardiac MRI. Secondary objectives include 1) determine the evolution of left ventricular remodeling on cardiac MRI in patients with HER2+ early breast cancer, 2) understand the mechanism of trastuzumab mediated cardiac toxicity by assessing for the presence of myocardial injury and apoptosis on serum biomarkers and cardiac MRI, and 3) correlate cardiac biomarkers of myocyte injury and extra-cellular matrix remodeling with left ventricular remodeling on cardiac MRI in patients with HER2+ early breast cancer.

Discussion

Cardiac toxicity as a result of cancer therapies is now recognized as a significant health problem of increasing prevalence. To our knowledge, MANTICORE will be the first randomized trial testing proven heart failure pharmacotherapy in the prevention of trastuzumab-mediated cardiotoxicity. We expect the findings of this trial to provide important evidence in the development of guidelines for preventive therapy.

Trial Registration

ClinicalTrials.gov: NCT01016886

【 授权许可】

   
2011 Pituskin et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Canadian Cancer Statistics Toronto, Canada; 2010:0835-2976.
• [2]Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235(4785):177-182.
• [3]Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244(4905):707-712.
• [4]Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11):783-792.
• [5]Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, et al.: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20(3):719-726.
• [6]Baselga J, Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P: Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005, 23(10):2162-2171.
• [7]Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, et al.: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23(19):4265-4274.
• [8]Baselga J, Perez EA, Pienkowski T, Bell R: Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 2006, 11(Suppl 1):4-12.
• [9]Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353(16):1673-1684.
• [10]Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG, et al.: Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007, 25(25):3859-3865.
• [11]Slamon DJ, Robert N, et al.: Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: a second interim efficacy analysis. In San Antonio Breast Cancer Symposium: 2006. San Antonio, TX; 2006.
• [12]Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ: Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment. J Clin Oncol 2005, 23(31):7820-7826.
• [13]Wadhwa D, Fallah-Rad N, Grenier D, Krahn M, Fang T, Ahmadie R, Walker JR, Lister D, Arora RC, Barac I, et al.: Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res Treat 2009, 117(2):357-364.
• [14]McArthur HL, Chia S: Cardiotoxicity of trastuzumab in clinical practice. N Engl J Med 2007, 357(1):94-95.
• [15]Cohn JN, Ferrari R, Sharpe N: Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000, 35(3):569-582.
• [16]Mann DL, Bristow MR: Mechanisms and Models in Heart Failure: The Biomechanical Model and Beyond. Circulation 2005, 111(21):2837-2849.
• [17]Vasan RS, Larson MG, Benjamin EJ, Evans JC, Levy D: Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med 1997, 336(19):1350-1355.
• [18]Haykowsky MJ, Liang Y, Pechter D, Jones LW, McAlister FA, Clark AM: A meta-analysis of the effect of exercise training on left ventricular remodeling in heart failure patients: the benefit depends on the type of training performed. J Am Coll Cardiol 2007, 49(24):2329-2336.
• [19]Haykowsky MJ, Mackey JR, Thompson RB, Jones LW, Paterson DI: Adjuvant Trastuzumab Induces Ventricular Remodeling Despite Aerobic Exercise Training. Clin Cancer Res 2009, 15(15):4963-4967.
• [20]Telli ML, Hunt SA, Carlson RW, Guardino AE: Trastuzumab-Related Cardiotoxicity: Calling Into Question the Concept of Reversibility. J Clin Oncol 2007, 25(23):3525-3533.
• [21]St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moye LA, Dagenais GR, Lamas GA, Klein M, Sussex B, Goldman S, et al.: Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994, 89(1):68-75.
• [22]Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, Shelton B: Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 1995, 91(10):2573-2581.
• [23]Ferrari R: Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 2006, 166(6):659-666.
• [24]Abdulla J, Barlera S, Latini R, Kjoller-Hansen L, Sogaard P, Christensen E, Kober L, Torp-Pedersen C: A systematic review: effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction. Eur J Heart Fail 2007, 9(2):129-135.
• [25]Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group Lancet 1997, 349(9049):375-380.
• [26]Bellenger NG, Rajappan K, Rahman SL, Lahiri A, Raval U, Webster J, Murray GD, Coats AJ, Cleland JG, Pennell DJ: Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study. Heart 2004, 90(7):760-764.
• [27]Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Inanc T, Oguzhan A, Eryol NK, Topsakal R, et al.: Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy. Journal of the American College of Cardiology 2006, 48(11):2258-2262.
• [28]Cardinale D, Lamantia G, Cipolla CM: Troponin I and cardiovascular risk stratification in patients with testicular cancer. J Clin Oncol 2006, 24(21):3508. author reply 3508-3509
• [29]Lipshultz SE, Lipsitz SR, Sallan SE, Simbre VC, Shaikh SL, Mone SM, Gelber RD, Colan SD: Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002, 20(23):4517-4522.
• [30]Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Inanc T, Oguzhan A, Eryol NK, Topsakal R, et al.: Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006, 48(11):2258-2262.
• [31]Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, Cinieri S, Martinelli G, Cipolla CM, Fiorentini C: Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000, 36(2):517-522.
• [32]Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973, 32(2):302-314.
• [33]Jenkins C, Moir S, Chan J, Rakhit D, Haluska B, Marwick TH: Left ventricular volume measurement with echocardiography: a comparison of left ventricular opacification, three-dimensional echocardiography, or both with magnetic resonance imaging. Eur Heart J 2009, 30(1):98-106.
• [34]Bellenger N, Pennell D: Magnetic resonance imaging in cardiology. J R Coll Physicians Lond 1999, 33(1):12-18.
• [35]Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ: Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2000, 2(4):271-278.
• [36]Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJ, Cleland JG, Pennell DJ: Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J 2000, 21(16):1387-1396.
• [37]Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, Lamantia G, Colombo N, Cortinovis S, Dessanai MA, et al.: Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28(25):3910-3916.
• [38]Lenihan DJMM, Baysinger KB, et al.: Superior detection of cardiotoxicity during chemotherapy using biomarkers. In Heart Failure Society of America: September 17 2007. Washington, DC; 2007.
• [39]Cardinale D, Sandri MT: Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis 53(2):121-129.
• [40]Querejeta R, Varo N, Lopez B, Larman M, Artinano E, Etayo JC, Martinez Ubago JL, Gutierrez-Stampa M, Emparanza JI, Gil MJ, et al.: Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000, 101(14):1729-1735.
• [41]Braunwald E: Biomarkers in Heart Failure. N Engl J Med 2008, 358(20):2148-2159.
• [42]Cicoira M, Rossi A, Bonapace S, Zanolla L, Golia G, Franceschini L, Caruso B, Marino PN, Zardini P: Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J Card Fail 2004, 10(5):403-411.
• [43]Zannad F, Alla F, Dousset B, Perez A, Pitt B: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000, 102(22):2700-2706.
• [44]Iraqi W, Rossignol P, Angioi M, Fay R, Nuee J, Ketelslegers JM, Vincent J, Pitt B, Zannad F: Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 2009, 119(18):2471-2479.
• [45]Lopez B, Gonzalez A, Diez J: Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation 121(14):1645-1654.
• [46]Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, et al.: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369(9555):29-36.
• [47]Mazurek S, Eigenbrodt E: The tumor metabolome. Anticancer Res 2003, 23(2A):1149-1154.
• [48]Slupsky CM, Steed H, Wells TH, Dabbs K, Schepansky A, Capstick V, Faught W, Sawyer MB: Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin Cancer Res 16(23):5835-5841.
• [49]Samuel JL, Schaub MC, Zaugg M, Mamas M, Dunn WB, Swynghedauw B: Genomics in cardiac metabolism. Cardiovasc Res 2008, 79(2):218-227.
• [50]Marziliano N, Grasso M, Pilotto A, Porcu E, Tagliani M, Disabella E, Diegoli M, Pasotti M, Favalli V, Serio A, et al.: Transcriptomic and proteomic analysis in the cardiovascular setting: unravelling the disease? J Cardiovasc Med (Hagerstown) 2009, 10(5):433-442.
• [51]Damaraju SSB, Ghosh S, Pituskin E, Tuszynski J, Cass CE, Mackey JR: Germline copy number polymorphisms associated with toxicity from adjuvant docetaxel. In San Antonio Breast Cancer Symposium: December 8-12 2010. San Antonio TX; 2010.
• [52]Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR: Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007, 50(15):1435-1441.